Alzheimer's disease nursing: clinical reference guide

Alzheimer’s disease (AD) is the most common cause of dementia, accounting for 60–80% of all dementia cases and affecting more than six million Americans. It is a progressive, irreversible neurodegenerative disorder characterized by amyloid plaque deposition, neurofibrillary tangles, synaptic loss, and widespread cortical atrophy. For nursing students, Alzheimer’s disease is essential NCLEX content because it demands competency across domains that rarely overlap in other conditions: cognitive assessment, behavioral management, safety surveillance, end-of-life planning, caregiver support, and a pharmacology profile unlike any other disease class. This reference covers everything you need — pathophysiology, both major staging systems, validated assessment tools including the PAINAD scale for pain in non-verbal patients, nursing interventions organized by priority, a complete pharmacology table, complication management, end-of-life considerations, and nine NCLEX-focused clinical reasoning tips.

Quick reference: Alzheimer’s disease at a glance

Pathophysiology

Alzheimer’s disease results from the accumulation of two abnormal protein aggregates that disrupt neuronal function, synaptic communication, and ultimately cell survival: amyloid plaques and neurofibrillary tangles.

Amyloid plaques

Beta-amyloid (Aβ) is a peptide fragment generated when the amyloid precursor protein (APP) is cleaved by beta-secretase and gamma-secretase enzymes. In healthy individuals, Aβ is cleared efficiently. In Alzheimer’s disease, clearance fails and Aβ monomers aggregate into oligomers, which are highly neurotoxic, and then into insoluble senile plaques deposited in the extracellular space between neurons. Amyloid plaques disrupt synaptic function, trigger neuroinflammation, and activate downstream tau pathology. The amyloid cascade hypothesis holds that Aβ accumulation is the initiating event in AD pathogenesis; this model underpins the rationale for amyloid-targeting therapies such as lecanemab and donanemab.

Neurofibrillary tangles

Tau is a microtubule-associated protein that stabilizes the intracellular scaffolding neurons use to transport nutrients and organelles along axons. In Alzheimer’s disease, tau becomes hyperphosphorylated and detaches from microtubules, causing the scaffold to collapse. The detached tau then aggregates into paired helical filaments that form neurofibrillary tangles inside neurons. Tangles correlate more closely with symptom severity than plaques do — as tangle pathology spreads from the entorhinal cortex and hippocampus to associative cortical areas, cognitive decline progresses predictably.

Cholinergic deficit

The nucleus basalis of Meynert in the basal forebrain is the primary source of cholinergic projections to the hippocampus and cortex. These cholinergic pathways are critical to encoding new memories and supporting attention. In Alzheimer’s disease, nucleus basalis neurons are among the earliest and most severely affected — acetylcholine synthesis falls substantially, and this cholinergic deficit is the primary pharmacological target of approved treatments. Cholinesterase inhibitors work by slowing the breakdown of acetylcholine in the synaptic cleft, partially compensating for reduced synthesis.

Neuroanatomical progression

Alzheimer’s pathology follows a characteristic anatomical trajectory. Entorhinal cortex and hippocampus are affected first, explaining why short-term memory loss — the inability to encode new experiences — is the hallmark early symptom. As pathology spreads to parietal and temporal association cortices, patients develop visuospatial deficits, aphasia, and apraxia. Frontal lobe involvement eventually produces executive dysfunction, behavioral disinhibition, and personality change. In late-stage disease, the motor cortex and subcortical structures are affected, leading to rigidity, mutism, incontinence, and loss of basic motor function.

Staging systems

Two staging frameworks are used in clinical and NCLEX contexts: the Alzheimer’s Association clinical stages (early, middle, late) and the Global Deterioration Scale (GDS), also called the Reisberg Scale, which provides seven stages with more granular functional descriptors.

Alzheimer’s Association stages

Global Deterioration Scale (GDS)

Nursing assessment

Comprehensive nursing assessment in Alzheimer’s disease spans cognitive function, behavioral symptoms, activities of daily living, pain, and safety.

Cognitive assessment tools

Mini-Mental State Examination (MMSE) — Scored 0–30. Tests orientation (10 points), registration (3 points), attention and calculation (5 points — serial sevens or WORLD backward), recall (3 points), language (8 points), and visuospatial ability (1 point — pentagon copying). Scoring thresholds: 24–30 = normal; 18–23 = mild impairment; 10–17 = moderate; below 10 = severe. Note that MMSE scores are influenced by education level and literacy; interpret results in context.

Montreal Cognitive Assessment (MoCA) — Scored 0–30; more sensitive than the MMSE for mild cognitive impairment (MCI). Adds executive function testing (Trail Making, clock drawing, abstraction), more demanding recall tasks, and visuospatial tests. Score below 26 is considered abnormal. The MoCA is the preferred screening tool for detecting early-stage AD and MCI.

Functional Assessment Staging Test (FAST) — A 7-stage scale (with substages in stages 6 and 7) that tracks functional rather than cognitive decline. FAST is particularly useful in moderate-to-severe AD when cognitive testing becomes unreliable, and it is used to establish hospice eligibility (FAST 7a or beyond).

Behavioral and psychological symptom assessment

Behavioral and psychological symptoms of dementia (BPSD) affect up to 90% of patients with AD at some point and are the leading driver of caregiver burnout and nursing home placement. Assessment should cover:

• Agitation and aggression — frequency, triggers, time of day (sundowning pattern?), preceding events
• Wandering — time and circumstances; risk of elopement; exit-seeking behavior
• Sundowning — onset typically late afternoon to early evening; worsens with fatigue, low light, overstimulation, or disrupted routine
• Psychotic features — visual hallucinations, paranoid delusions (most common: “people are stealing from me”)
• Depression and apathy — use the Cornell Scale for Depression in Dementia (CSDD) or Geriatric Depression Scale adapted for dementia
• Sleep disturbances — fragmented sleep, reversed sleep-wake cycle

ADL and functional assessment

Use the Barthel Index or Katz Index of Independence in Activities of Daily Living to document functional status. Track the order in which ADLs are lost — they typically decline in reverse developmental order: complex instrumental ADLs first (finances, medications, driving), then basic ADLs in this approximate sequence: bathing and grooming → dressing → toileting → continence → feeding → mobility.

Pain assessment in cognitively impaired patients

Patients with moderate-to-severe AD cannot reliably self-report pain. Use the PAINAD scale (Pain Assessment in Advanced Dementia):

Total score 0–10: 1–3 = mild pain; 4–6 = moderate; 7–10 = severe. Treat score ≥4 with analgesic intervention and reassess.

Safety assessment

Conduct a structured safety evaluation at every encounter:

• Fall risk — Morse Fall Scale or STRATIFY; assess footwear, environment, gait aids
• Wandering risk — history of elopement, exit-seeking behavior, awareness of wandering pattern
• Driving — assess at diagnosis and at each stage transition; consider formal driving evaluation; mandatory reporting laws vary by state
• Medication management — ability to self-administer medications safely; pill organizers vs. supervised administration
• Home environment — stove safety (knob covers, automatic shut-offs), water temperature (scald prevention), unsecured exits, firearms

Nursing interventions

Safety: wandering prevention

Wandering occurs in up to 60% of patients with Alzheimer’s disease and is associated with serious injury, hypothermia, traffic accidents, and death. Interventions include:

• Environmental modifications — door alarms, coded keypads, door camouflage (covering door handles or painting exits the same color as the wall), secured outdoor areas
• Bed and chair sensors — alerting staff or caregivers when the patient rises unsupported
• ID bracelet or GPS tracking device — enrolling in the Alzheimer’s Association Safe Return program
• Structured activity — increasing daytime engagement and physical activity to reduce restlessness
• Identifying triggers — boredom, pain, full bladder, hunger, anxiety; treat the underlying cause before adding behavioral measures

Communication strategies

Standard corrective communication (“That happened 10 years ago” / “Your mother is dead”) causes distress in patients with Alzheimer’s disease and does not produce insight. Evidence supports the following approaches:

Validation therapy — Meet the patient in their emotional reality rather than correcting their factual errors. If a patient believes she needs to pick up her children from school, acknowledge the feeling: “It sounds like you’re a wonderful mom. Tell me about your children.” Redirect after the emotional need is acknowledged.

Simple, direct language — Use short sentences with one idea or question at a time. Speak slowly, face the patient directly, and maintain eye contact. Avoid pronouns; use names instead of “he” or “she.”

Non-verbal communication — Tone of voice, facial expression, and touch often communicate more than words. A calm, warm tone reduces agitation even when words are not fully processed.

Reminiscence therapy — Engaging long-term memory (often preserved until late stages) through familiar music, photographs, and life-history conversation. Music from the patient’s young adulthood is particularly effective at reducing agitation and improving mood.

Music therapy — Personally meaningful music activates non-declarative memory pathways (relatively preserved in AD) and can reduce agitation, improve mood, and facilitate cooperation with care tasks.

ADL support

• Routine-based care — Perform care activities at the same time each day. Patients with AD retain procedural memory longer than episodic memory; consistent routines allow habitual behavior to guide participation even when explicit memory fails.
• Cueing hierarchy — Begin with verbal cues (“Lift your arm”), progress to gestural cues (demonstrating the action), then physical guidance (hand-over-hand assistance). Always use the least restrictive cue needed.
• Break tasks into single steps — Dressing, grooming, and bathing should be presented one step at a time, waiting for completion before proceeding.
• Adapted clothing and utensils — Velcro closures, elastic waistbands, weighted utensils, plate guards, and non-slip mats reduce frustration and preserve independence.

Nutrition and hydration

Malnutrition and dehydration are common in moderate-to-late AD due to forgetting to eat, reduced appetite, apraxia affecting utensil use, dysphagia, and behavioral resistance to eating. Interventions:

• Finger foods — sandwiches, cheese cubes, fruit slices, and other foods that can be eaten while walking allow patients who cannot sit still to consume calories during activity
• Preferred foods — work with family to identify lifelong food preferences; maintaining preferred tastes maximizes intake
• Small, frequent meals — reduce the cognitive demand of a full meal; offer snacks between meals
• Dysphagia management — screen for swallowing difficulty (coughing after eating or drinking, wet voice quality, drooling, prolonged mealtimes); refer to speech-language pathology for formal swallowing evaluation; thicken liquids and modify food textures per SLP recommendations; always seat patient fully upright at 90 degrees for meals and 30–45 minutes after
• Adequate hydration — offer fluids frequently throughout the day using preferred beverages; avoid relying on thirst sensation, which is diminished in older adults with dementia
• Weight monitoring — weekly weights; report >5 lbs in one week or >10 lbs in one month

Behavioral management: sundowning protocol

Sundowning (late-day confusion syndrome) refers to the cluster of increased agitation, confusion, disorientation, and wandering that peaks in the late afternoon and early evening. Nursing interventions follow a non-pharmacological-first hierarchy:

1. Maximize morning light exposure — natural light resets the circadian rhythm; open blinds and encourage outdoor time in the morning
2. Structured afternoon activity — scheduled, familiar activities at the sundowning peak time (typically 3–6 pm) reduce behavioral escalation
3. Minimize overstimulation — reduce noise, visitors, and environmental complexity in the late afternoon
4. Assess and treat underlying causes — pain, full bladder, hunger, constipation, fatigue, and infection all worsen sundowning
5. Maintain consistent sleep-wake schedule — avoid daytime napping exceeding 30 minutes; keep bedtime consistent
6. Environmental cues — adequate indoor lighting in the evening; avoid sudden transition from bright to dark environments

Restraints (physical or chemical) are a last resort and require a physician order, documented rationale, and regular reassessment. Chemical restraint with antipsychotics carries an FDA black box warning in elderly patients with dementia due to increased risk of stroke and death.

Caregiver support

Caregiver burnout affects the majority of family caregivers of patients with AD. It is associated with depression, physical illness, medication errors, and patient abuse. Nursing interventions:

• Assess caregiver stress at every visit — use the Zarit Burden Interview or similar validated tool
• Provide anticipatory guidance — educate caregivers about what to expect at each disease stage
• Connect with community resources — Alzheimer’s Association helpline (1-800-272-3900), local memory care support groups, respite care programs, and adult day programs
• Respite care — encourage regular scheduled breaks from caregiving; respite services include adult day programs, in-home respite workers, and short-stay memory care
• Legal and financial planning — encourage early engagement with elder law attorneys for durable power of attorney, healthcare proxy, and estate planning while the patient retains legal capacity

Pharmacology

Complications

Aspiration pneumonia

The leading cause of death in Alzheimer’s disease. Dysphagia develops as cortical and brainstem function deteriorates. Prevention is the primary nursing role: upright positioning during and after meals, appropriate diet texture modification per SLP evaluation, adequate supervision during eating, and monitoring for silent aspiration (aspiration without coughing reflex, common in cognitively impaired patients). Signs of aspiration pneumonia: fever, tachycardia, increased respiratory rate, wet cough, decreased O2 saturation, and altered mental status (AMS may be the only sign in late-stage AD).

Falls and fractures

Falls are 2–3 times more common in patients with AD than in cognitively intact older adults. Contributing factors include gait disturbance, visuospatial impairment, psychotropic medications, orthostatic hypotension, and impulsivity. Hip fracture in late-stage Alzheimer’s disease carries extremely high morbidity and mortality. Fall prevention requires a multi-factorial approach: environmental modification, appropriate footwear, physical therapy for strength and balance, medication review (remove or reduce fall-risk drugs), and bed/chair alarms.

Dehydration and malnutrition

Progressive weight loss in Alzheimer’s disease is multifactorial: reduced appetite, forgetting to eat, dysphagia, increased metabolic demand from agitation, and depression. Monitor weights weekly, track intake, and involve a registered dietitian early. Tube feeding in late-stage AD does not improve outcomes (survival, quality of life, aspiration risk, or comfort) and is generally inconsistent with goals of comfort-focused care — document and respect advance directives regarding artificial nutrition.

Pressure injuries

Late-stage Alzheimer’s disease confines patients to bed or chair, and pain communication is absent. Implement standard pressure injury prevention: repositioning every 2 hours, pressure-redistribution mattresses, moisture management, adequate nutrition, and skin inspection with each care episode using the Braden Scale to guide risk stratification.

Urinary tract infections

UTIs are among the most common infections in patients with AD. They frequently present atypically — without dysuria or fever — as acute behavioral change, increased confusion, agitation, or functional decline. Any sudden worsening of cognition or behavior should prompt evaluation for infection (UA with culture, CBC, metabolic panel). Treat confirmed UTIs with targeted antibiotics; behavioral symptoms often resolve within 48–72 hours of treatment.

Caregiver burnout

Caregiver burnout is a clinical complication — it directly causes patient harm through medication errors, neglect, and abuse. Assess caregiver mental and physical health, ensure respite resources are in place, and know your facility’s and state’s adult protective services (APS) reporting obligations for elder mistreatment.

End-of-life considerations

Goals of care conversations

Advance care planning in Alzheimer’s disease should begin at diagnosis, while the patient retains decision-making capacity. Delay is a clinical error — by the time families recognize the need for planning, the patient can no longer participate meaningfully. Nursing role: identify when the patient has capacity, facilitate conversations between the patient, family, and physician, and ensure the following documents are in place:

• Durable power of attorney for healthcare (DPAHC) — designates a healthcare proxy
• Advance directive / living will — documents treatment preferences for specific scenarios (CPR, mechanical ventilation, artificial nutrition, hospitalization)
• POLST form (Physician Orders for Life-Sustaining Treatment) — portable, immediately actionable physician orders that translate advance directive wishes into specific medical orders; appropriate in moderate-to-late stage AD

Hospice eligibility

Medicare hospice eligibility in Alzheimer’s disease requires a prognosis of six months or less if the disease follows its expected course AND that the patient has reached FAST stage 7a or beyond (FAST 7a = speech limited to approximately six or fewer intelligible words in a day) AND has experienced at least one of the following in the past 12 months: aspiration pneumonia, pyelonephritis or other upper UTI, septicemia, multiple stage 3–4 pressure injuries despite care, persistent fever recurrences, or 10% weight loss in 6 months (or serum albumin below 2.5 g/dL).

Comfort-focused care

Reorienting goals from curative to comfort-focused in late-stage AD involves:

• Medication deprescribing — reviewing and discontinuing medications that treat conditions whose benefits are not realizable in the patient’s current state (statins, blood pressure medications at high thresholds, preventive therapies)
• Oral care — critical for comfort and prevention of oral infections in non-verbal patients
• Pain management — PAINAD-guided analgesic titration; do not undertreat pain because the patient cannot verbally report it
• Emotional and spiritual support for family — dying from dementia is a prolonged and frequently traumatic experience for families; interdisciplinary support including chaplaincy and social work is essential

NCLEX tips

1. Sundowning timing is the afternoon — know it. Sundowning peaks in the late afternoon and early evening, not overnight. The NCLEX frequently tests whether students confuse sundowning (late afternoon) with nocturnal confusion (a separate phenomenon). Non-pharmacological interventions — structured activity, morning light exposure, reduced afternoon stimulation — come before medications.

2. Validation therapy, not reality orientation. When a patient with Alzheimer’s disease says her deceased mother is coming to visit, the correct nursing response enters her emotional reality and acknowledges the feeling — do not correct the factual error. Reality orientation is appropriate for delirium and short-term confusion; it is harmful and ineffective in moderate-to-severe Alzheimer’s disease.

3. Safety is always the priority intervention. When an NCLEX question asks which intervention to implement first for a patient with Alzheimer’s disease, safety (wandering prevention, fall prevention, aspiration prevention) takes priority over comfort, communication, or medication administration unless an acute life-threatening situation is described.

4. Cholinesterase inhibitors treat the cholinergic deficit — know the class mechanism. Donepezil, rivastigmine, and galantamine all work by inhibiting acetylcholinesterase to increase synaptic acetylcholine. They treat symptoms but do not alter disease course. Side effects are cholinergic: bradycardia (check pulse before giving), GI upset (nausea, diarrhea), urinary frequency, and increased secretions. Never confuse these with memantine, which is an NMDA antagonist targeting glutamate, not acetylcholine.

5. Use the PAINAD scale for pain assessment in non-verbal patients. A patient with severe Alzheimer’s disease cannot self-report pain. The NCLEX expects you to know that the PAINAD scale (five domains: breathing, vocalization, facial expression, body language, consolability) is the validated tool for this population. A score of 4 or above indicates significant pain requiring analgesic intervention. Assessing pain only by self-report is a care failure in this population.

6. Aspiration pneumonia is the primary cause of death — aspiration precautions are mandatory. Late-stage Alzheimer’s disease causes progressive dysphagia. Nursing priorities: 90-degree upright positioning during and 30–45 minutes after meals, SLP evaluation for dysphagia, appropriate diet texture modification, and monitoring for silent aspiration (no cough reflex present). A wet or gurgly voice after swallowing is an aspiration red flag.

7. Capacity vs. competence — understand the distinction. Decision-making capacity is a clinical determination made by the treating clinician. Competence is a legal determination made by a court. A patient with Alzheimer’s disease may lack capacity for complex financial decisions while retaining capacity to consent to or refuse a specific medical treatment. Nurses assess behavior and function; they do not determine legal competence. Document specific observed behaviors rather than global statements about a patient’s “mental status.”

8. Antipsychotics carry an FDA black box warning in elderly patients with dementia. Atypical antipsychotics (quetiapine, risperidone, olanzapine) are used off-label for BPSD but increase the risk of stroke and death in elderly patients with dementia. They are a last resort after non-pharmacological interventions have failed. The NCLEX expects you to recognize the black box warning and prioritize non-pharmacological behavioral interventions first.

9. FAST stage 7a is the Medicare hospice eligibility threshold. Hospice is appropriate when speech is limited to six or fewer intelligible words per day (FAST 7a) plus one qualifying clinical complication in the past year. The NCLEX may test whether students know that tube feeding does not improve survival, aspiration risk, or comfort in late-stage Alzheimer’s disease, and is inconsistent with comfort-focused goals of care.

Internal links

For related clinical references:

• Parkinson’s disease nursing — the other major neurodegenerative disease with significant overlap in nursing management, fall prevention, and dysphagia care
• Multiple sclerosis nursing — another progressive neurological condition requiring mastery of functional assessment and symptom management
• Stroke nursing — vascular dementia frequently follows stroke; many Alzheimer’s patients have concurrent cerebrovascular disease
• Glasgow Coma Scale — neurological assessment fundamentals relevant to any patient with altered cognitive status
• Head-to-toe assessment — foundational assessment skills for identifying complications in non-verbal patients
• Drug classifications in nursing — understanding pharmacological drug classes including cholinesterase inhibitors and NMDA antagonists